Vaccitech reports promising interim efficacy analysis in Phase 1b/2a clinical study in chronic HBV

OXFORD, United Kingdom, Dec. 07, 2021 — Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced a promising interim analysis of safety and efficacy data from the HBV002 study, including a review of surface antigen (HBsAg) levels in CHB patients.

Read the full release here.